Livio Françoise
Service de pharmacologie clinique, Département des laboratoires, CHUV, 1011 Lausanne.
Rev Med Suisse. 2018 Jan 10;14(588-589):81-84.
The main pharmacovigilance updates in 2017 are reviewed. Denosumab : rebound-associated multiple vertebral fractures after discontinuation. Canagliflozine: increased risk of foot/leg amputations. Biologic and targeted cancer therapies, direct-acting antivirals for chronic hepatitis C: risk of hepatitis B reactivation. Checkpoint inhibitors : immune-related adverse events and graft rejection. Fingolimod : rebound-associated reactivation of MS following withdrawal. Daclizumab: risk of severe liver injury leading to restricted use in MS patients. Posaconazole: risk of overexposure when switching from oral suspension to tablets. Voriconazole: cutaneous squamous cell carcinoma under long-term therapy. Proton pump inhibitors : early exposure might increase fracture risk in young children.
回顾了2017年主要的药物警戒更新情况。地诺单抗：停药后与反弹相关的多发性椎体骨折。卡格列净：足部/腿部截肢风险增加。生物和靶向癌症治疗药物、慢性丙型肝炎直接作用抗病毒药物：乙型肝炎再激活风险。检查点抑制剂：免疫相关不良事件和移植排斥反应。芬戈莫德：撤药后与反弹相关的多发性硬化症再激活。达利珠单抗：严重肝损伤风险导致其在多发性硬化症患者中的使用受限。泊沙康唑：从口服混悬液转换为片剂时存在暴露过量风险。伏立康唑：长期治疗下的皮肤鳞状细胞癌风险。质子泵抑制剂：幼儿早期接触可能增加骨折风险。
